EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Topical tacrolimus versus corticosteroids in childhood moderate-to-severe atopic dermatitis and the impact on airway inflammation: a long-term randomized open-label study

Miia Perälä iD, Alexander Salava iD, Pekka Malmberg, Anna S Pelkonen, Mika J Mäkelä, Anita Remitz

Clinical and Experimental Dermatology · 2023

DOI: 10.1093/ced/llad098 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Experimental Dermatology, 2023. Verfasst von Miia Perälä und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Allergology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Eczema. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pediatric Research Foundation, Päivikki and Sakari Sohlberg Foundation, Finnish Dermatological Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Childhood atopic dermatitis (AD) is often followed by other atopic comorbidities such as asthma.

Aim

To compare the effectiveness of topical tacrolimus (TAC) and topical corticosteroids (TCSs) and their impact on airway inflammation and bronchial hyperresponsiveness in patients with paediatric AD.

Methods

This was a 3-year randomized open-label comparative follow-up study of 152 1–3-year-old children with moderate-to-severe AD (trial registration: EudraCT2012-002412-95). Frequent study visits including clinical examinations, laboratory investigations (total IgE, specific IgEs, blood eosinophils), skin prick and respiratory function tests to assess airway inflammation and bronchial hyperresponsiveness (exhaled nitric oxide, airway responsiveness to exercise and methacholine) were performed.

Results

Changes in eczema parameters at 36 months were similar in the TCS and TAC groups for mean body surface area (BSA) difference 1.4 [95% confidence interval (CI) –1.48 to 4.19); P = 0.12], mean Eczema Area and Severity Index (EASI) difference 0.2 (95% CI –1.38 to 1.82; P = 0.2), mean Investigator’s Global Assessment (IGA) difference, 0.3 (95% CI –0.12 to 0.67; P = 0.12) and mean transepidermal water loss (TEWL) difference at the eczema site, –0.3 (95% CI –4.93 to 4.30; P = 0.96) and at the control site, 1.4 (95% CI –0.96 to 3.60, P = 0.19). The control-site TEWL increased more towards the end of follow-up in the TCS vs. TAC group (mean change difference –4.2, 95% CI –8.14 to –0.29; P = 0.04). No significant impact on development of airway inflammation or bronchial hyperresponsiveness occurred in early effective eczema-treatment responders vs. others (‘early’ vs. ‘other’ response was defined as the difference in treatment response to airway outcomes in BSA, EASI or IGA at 3 months).

Conclusion

Children with moderate-to-severe AD benefit from long-term treatment with TCS or TAC. There were no significant differences in treatment efficacy. No differences in the impact on airways occurred between early effective treatment responders vs. others.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicEczemaHumansChildChild, PreschoolTacrolimusFollow-Up StudiesAdrenal Cortex HormonesInflammationTreatment OutcomeImmunoglobulin ASeverity of Illness IndexDouble-Blind Method

Substanzen

TacrolimusAdrenal Cortex HormonesImmunoglobulin A

Autor:innen und Institutionen

  • Department of Dermatology and Allergology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

ORCID-Profile: Miia Perälä, Alexander Salava

Förderung

  • Pediatric Research Foundation
  • Päivikki and Sakari Sohlberg Foundation
  • Finnish Dermatological Society
  • Allergy Research Foundation
  • Orion Research Foundation
  • Ida Montin Foundation
  • Emil Aaltonen Foundation
  • Astellas Pharma

Zitieren

APA

Perälä, M., Salava, A., Malmberg, P., Pelkonen, A. S., Mäkelä, M. J., & Remitz, A. (2023). Topical tacrolimus versus corticosteroids in childhood moderate-to-severe atopic dermatitis and the impact on airway inflammation: a long-term randomized open-label study. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llad098

Vancouver

Perälä M, Salava A, Malmberg P, Pelkonen AS, Mäkelä MJ, Remitz A. Topical tacrolimus versus corticosteroids in childhood moderate-to-severe atopic dermatitis and the impact on airway inflammation: a long-term randomized open-label study. Clinical and Experimental Dermatology. 2023. doi:10.1093/ced/llad098

BibTeX
@article{Perl2023,
  author = {Perälä, Miia and Salava, Alexander and Malmberg, Pekka and Pelkonen, Anna S and Mäkelä, Mika J and Remitz, Anita},
  title = {Topical tacrolimus versus corticosteroids in childhood moderate-to-severe atopic dermatitis and the impact on airway inflammation: a long-term randomized open-label study},
  journal = {Clinical and Experimental Dermatology},
  year = {2023},
  doi = {10.1093/ced/llad098}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche